Tirzepatide Reduces Albuminuria in Patients with T2D: Post-hoc Pooled Analysis of SURPASS 1-5 | Synapse

⌘+K

Keep reading

Synapse has enriched 10 related papers. Consider them for comparative context:

1Kidney Parameters with Tirzepatide in Obesity with or without Type 2 DiabetesClinical Trial · 2025 · 22 citations
2Renal effects and safety of tirzepatide in subjects with and without diabetes: A systematic review and meta-analysismeta-analysis · 2024 · 10 citations
3Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical programcohort · 2023 · 55 citations
4Tirzepatide for the treatment of adults with type 2 diabetes: An endocrine perspectiveLate-Phase Clinical Trial · 2022 · 127 citations
5A comparison of the effects of tirzepatide and dulaglutide on major kidney events in people with type 2 diabetes: pre-specified exploratory analyses of the SURPASS-CVOT trial.Original Research · 2026 · 9 citations
6Reduction of prevalence of patients meeting the criteria for metabolic syndrome with tirzepatide: a post hoc analysis from the SURPASS Clinical Trial Program2024 · 12 citations
7Tirzepatide reduces the predicted risk of developing type 2 diabetes in people with obesity or overweight: Post hoc analysis of the <scp>SURMOUNT</scp> ‐1 trialOriginal Research · 2023 · 44 citations
8Tirzepatide reduces HbA1c and body weight significantly more than placebo or semaglutide irrespective of baseline beta-cell function: post-hoc analysis from SURPASS-1 and SURPASS-22024 · 2 citations
9Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults with Obesity (SURMOUNT-4)Diabetologie und Stoffwechsel · 2024
10Tirzepatide Improves HRQoL Compared to Insulin Lispro in Poorly Controlled Basal Insulin-treated Adults with Long-standing T2D (SURPASS-6)Diabetologie und Stoffwechsel · 2024

More from Diabetologie und Stoffwechsel

More from University of Washington